Evicenter
MarkdownMedical informationP&T meetings
Claseprubart (DNTH103)

Generalized myasthenia gravis

Launch
Not announced
Last updated
120 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Limitations of current therapies

9 evidence topics · 11 sources

Summary

10% to 20% of patients continue to have long-standing moderate or severe weakness after treatment with at least two different immunosuppressive drugs at high doses, and Tice et al. (2022) state that about 20,000 patients with generalized myasthenia gravis are estimated to be intolerant or to have an inadequate response to conventional treatment options. Upward of thirty percent of patients do not benefit from complement inhibition. In claims data from 8833 patients with generalized myasthenia gravis, incident glucocorticoid toxicities occurred in 61.9% of patients with any glucocorticoid use, compared with 52.3% without, and annual all-cause costs were more than twice as high ($76,381 vs $35,309). Soliris increases the risk of serious meningococcal infections, requires meningococcal vaccination at least 2 weeks before the first dose, and, like Zilbrysq, is available only through a REMS program. Vyvgart may increase the risk of infection. Gilhus et al. list the need for meningococcal vaccination before starting treatment, recommended pneumococcal vaccination, and regular intravenous or subcutaneous injections as limitations, and a company presentation states that 40% of patients discontinue Vyvgart within one year. ICER estimated an incremental cost-effectiveness ratio of $5,210,000 per QALY/evLYG for eculizumab, and high drug costs limit access to complement inhibitors and FcRn blockers in most countries.

Meningococcal infection risk, vaccination, and REMS with complement C5 inhibitors
Cost and cost-effectiveness of targeted biologics